No.25 Central Pharmaceutical Joint Stock Co
UUPCOM:UPH7,200.00
VND
0.00
(0.00%)
ISIN
VN000000UPH5
Return %
Stock
S&P 500
1Y
-27.27
14.20
3Y
-8.86
81.12
5Y
-43.75
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Ho Chi Minh City Vietnam
- IPO Date
- Dec 29, 2016
- Website
- uphace.vn
- Similar Companies
- Business
- No.25 Central Pharmaceutical Joint Stock Co (UPCOM: UPH), commercially branded as UPHACE, is a Vietnam-based pharmaceutical company primarily engaged in the development, manufacture, and commercial distribution of generic pharmaceuticals, over-the-counter (OTC) medications, medicinal chemicals, and health supplements. Originally established in 1993 as the No. 25 Central Pharmaceutical Enterprise and transitioned into a joint-stock entity in 2007, the company is headquartered in Ho Chi Minh City, Vietnam, and operates as a consolidated manufacturing subsidiary of OPC Pharmaceutical Joint Stock Company (OPC Pharma), with historical affiliation to Vietnam Pharmaceutical Corporation (Vinapharm). The company manufactures and markets a broad portfolio of pharmaceutical formulations across several core therapeutic categories, operating production facilities certified under World Health Organization Good Manufacturing Practice (WHO-GMP), Good Laboratory Practice (GLP), and Good Storage Practice (GSP) standards. Its primary product lines include analgesics and antipyretics, such as Paracetamol and Uphadol Extra; non-steroidal anti-inflammatory and anti-rheumatic drugs, such as Diclofenac and Rheumatin; antibiotic and anti-infective medications spanning beta-lactam and non-beta-lactam classes, such as Cefixime Uphace, Cefaclor Uphace, Cezirnate, and Tetracyclin; respiratory and ENT remedies, such as Rhinex nasal drops and Tercodin; gastrointestinal medications, such as Uphatin; and nutritional supplements and herbal healthcare products, including Dianvita Extra, multivitamin preparations, and Eucalyptus essential oils. These products are supplied in various finished dosage forms, including film-coated tablets, hard gelatin capsules, oral powders, granules, oral solutions, and topical liquids. Geographically, the company distributes its products across Vietnam through public hospital tenders, medical clinics, regional wholesale distributors, and nationwide retail pharmacy chains, while maintaining export operations to select markets in ASEAN countries, Africa, and Eastern Europe. In recent corporate and operational developments, No.25 Central Pharmaceutical Joint Stock Co has advanced the integration of its manufacturing operations and sales channels with parent company OPC Pharma, upgraded production processes to sustain stringent WHO-GMP compliance, expanded distribution partnerships across modern pharmaceutical retail chains, and strategically concentrated on high-demand essential generic formulations and consumer healthcare lines to bolster domestic market share.